Abstract
In this issue of Blood, Khaw et al show that in contrast to the impressive antileukemic activity achieved by sole BCL-2 inhibition in chronic lymphocytic leukemia (CLL), optimal antileukemic activity in pediatric acute lymphoblastic leukemia (ALL) xenografts required concurrent inhibition of both BCL-2 and BCL-XL.1.
Original language | English (US) |
---|---|
Pages (from-to) | 1316-1317 |
Number of pages | 2 |
Journal | Blood |
Volume | 128 |
Issue number | 10 |
DOIs |
|
State | Published - Sep 8 2016 |
Externally published | Yes |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology